We have recently shown that wild type (wt) mice are highly tolerant, while thyrotropin receptor (TSHR) knockout (KO) mice are susceptible, to immunization with the mouse (m) TSHR, the autoantigen in Graves' disease. However, because TSHR KO mice lack the endogenous TSHR, Graves-like hyperthyroidism cannot be expected to occur in these mice.
The Introduction
Graves' disease is a thyroid-specific autoimmune disease characterized by agonistic anti-thyrotropin receptor (TSHR) autoantibody (thyroid stimulating antibody, TSAb) that mediates overproduction of thyroid hormones (hyperthyroidism) and diffuse enlargement of the thyroid glands, and is frequently accompanied by extrathyroidal manifestations such as orbitopathy and dermopathy (1) (2) (3) (4) . We have previously established novel mouse models of experimental Graves-like hyperthyroidism in which hyperthyroidism can be efficiently induced in susceptible mouse strains (e.g., BALB/c) by repetitive immunizations with recombinant adenovirus expressing the human (h) full-length thyrotropin receptor (5) or its A-subunit (amino acids 1-289) (6) (Ad-hTSHR or Ad-hTSHR A-subunit). In these models, however, hyperthyroidism was transient, and intrathyroidal lymphocyte infiltration or extrathyroidal lesions were not observed.
Human TSHR is not an authentic autoantigen in mice, because homology between the hTSHR and mouse (m) TSHR is ~87 % at amino acid levels (7, 8) . Thus, in our models mentioned above, hyperthyroidism is induced by anti-hTSHR antibodies that cross-react with endogenously expressed mTSHR in mouse thyroid glands (9) . However, we have recently shown that immunization of wild type (wt) BALB/c mice with Ad-mTSHR A-subunit does not provoke an anti-TSHR immune response, whereas anti-mTSHR antibodies including TSAb can readily be induced in TSHR knockout (KO) mice (10) . These data strongly indicate that tolerance to mTSHR, the authentic autoantigen, is extremely strong in wt mice, and that this tolerance is absent in TSHR KO mice. However, TSHR KO mice lack the endogenous TSHR in their thyroid glands thus preventing us from studying development of Graves' hyperthyroidism/orbitopathy in these mice.
Because our goal is to establish an ideal Graves' mouse model using mTSHR as an autoantigen, we performed adoptive transfer experiments of splenocytes from TSHR KO mice into immune-deficient athymic nude mice expressing the endogenous TSHR in their thyroids as 4 well and also likely in their orbital tissues. We now show successful adoptive transfer of anti-mTSHR autoimmune response from TSHR KO mice to nude mice. Despite transient and infrequent hyperthyroidism and eventual hypothyroidism, induction of orbital lesions indicates that anti-TSHR immune response appears to play at least partly a role for the development of Graves' orbitopathy.
Materials and Methods

Mice
Female wt BALB/c mice (6 weeks old) and female athymic BALB/c nude mice (5 weeks old) were purchased from Charles River Japan Laboratory Inc. (Tokyo, Japan). TSHR KO BALB/c mice were previously generated by back-crossing TSHR KO B6/129 mice (11) (Jackson Laboratory Inc., Bar Harbor, ME, USA) with wt BALB/c mice for 6 successive generations (10) . All mice were kept in a specific pathogen free facility. Animal care and all experimental procedures were performed in accordance with the Guideline for Animal Experimentation of Nagasaki University with approval of the Institutional Animal Care and Use Committee.
Recombinant adenoviruses and immunization protocol
Construction, amplification and purification of non-replicative recombinant human adenovirus expressing the mTSHR A-subunit (Ad-mTSHR A-subunit) has been described previously (10) . TSHR KO mice were injected intramuscularly in the quadriceps with 100 l PBS containing 10 10 particles of adenovirus on two occasions at three-week-intervals. For long-term follow-up studies (Figure 1 ), mice were bled regularly during 24 weeks after the second immunization.
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Adoptive transfer of splenocytes
For adoptive transfer experiments (Figure 2 ), spleens were obtained from immunized mice 2 to 4 weeks after the final immunization or from naïve mice. For some studies, a group of mice was depleted of CD4 + CD25 + regulatory T cells (Tregs) by intraperitoneal injection of 500 g/mouse anti-CD25 monoclonal antibody (PC61) (12) 4 days prior to euthanization.
Splenocytes were injected intraperitoneally (i.p.) into nude BALB/c mice (5 x 10 7 in 100 l PBS/mouse). Groups of recipient mice were treated, after transfer, by i.p. injection of 100 g/mouse anti-cytotoxic T-lymphocyte antigen 4 (CTLA4; clone #UC10-4F10-11) and/or anti-programmed cell death 1 ligand 1 (PD-L1; clone #10F.9G2) monoclonal antibodies (both from Bio X Cell, Inc., West Lebanon, NH, USA), alone or in combination, twice a week for 8
weeks. Mice were bled regularly during 24 weeks after transfer.
Thyroxine (T 4 ) and TSH measurements
Serum free T 4 concentrations were measured by radioimmunoassay (RIA) as previously described (10) . Serum TSH was measured by a specific mouse TSH RIA as previously described (13) except that mouse TSH reference (AFP9090D) was used instead of mouse TSH/LH reference (AFP51718MP). The normal range was defined as the mean + 3 S.D. of untreated control mice.
TSHR antibody measurements
TSHR antibodies in mouse sera were determined using 3 different methods. The first assay for binding of TSHR antibodies to the native TSHR (irrespective of their function) used flow cytometry with Chinese hamster ovary (CHO) cells stably expressing the mTSHR (CHO-mTSHR). Briefly, the cells were incubated for 60 min with PBS containing mouse sera
(1:100 dilution) followed by FITC-conjugated anti-mouse IgG antibody (F2772, Sigma-Aldrich) for 60 min. Cells were analyzed using FACSCanto II as previously described 
Tg autoantibody measurements
Tg was purified from mouse thyroid glands as previously described (14) . ELISA wells were coated overnight with 100 l Tg protein (10 g/ml) and incubated with mouse sera (1:100 dilutions). After incubation with horseradish peroxidase-conjugated anti-mouse IgG (A3673, Sigma), color was developed using orthophenylene diamine and H 2 O 2 as substrate and optical density (OD) read at 492 nm.
Thyroid and orbital histology
Thyroid and retrobulbar histology was examined with hematoxylin and eosin (H & E)
staining of formalin-fixed tissue sections.
Immunohistochemistry was also performed to visualize macrophage infiltration in orbital tissues. Mice were anesthetized with pentobarbital and perfused via the left ventricle with cold 4% 
Statistical analysis
Data on the titers of antibodies were analyzed by t-test, and the successful transfer rates by chi-square. Statistical evaluation of cell counts was performed with Prism 5.01 (GraphPad software Inc, La Jolla, CA). Testing for significance was conducted using the Kruskal-Wallis one-way analysis of variance. Post testing was conducted with Bonferroni-Dunn's multiple comparison test. A 'p' value of less than 0.05 was considered statistically significant. 
Anti-TSHR antibodies and thyroid function following adoptive transfer of splenocytes from immunized TSHR KO mice
The in vivo effect of functional anti-TSHR antibodies in TSHR KO mice following immunization with Ad-mTSHR A-subunit ( Figure 1 ) cannot be examined because these mice lack expression of the target autoantigen TSHR. Therefore, we performed adoptive transfer of splenocytes from immunized TSHR KO BALB/c mice to immune deficient athymic nude BALB/c mice expressing the endogenous TSHR but lacking mature T or B cells. We anticipated that TSHR-reactive lymphocytes from TSHR KO mice would recognize the endogenously expressed TSHR in the recipient nude mice as an autoantigen and also that anti-TSHR antibodies produced would react with the endogenous TSHR in the recipient mice.
Circulating anti-TSHR autoantibodies were detected in 6/13 (46 %) of the recipient mice 4
weeks after adoptive transfer of splenocytes from the donor TSHR KO mice that were produced anti-TSHR antibodies after 2 immunizations with Ad-mTSHR A-subunit ( Figure 2A ; note that 9 most mice were sacrificed on 6th week, so that only 2 mice were followed up for 24 weeks). Serum T 4 and TSH levels were subsequently determined. Despite the highly successful transfer of antibody production, the incidence of hyperthyroidism was disappointedly low in the recipient mice. Thus, only 5/24 (21 %) mice were hyperthyroid 4 weeks after transfer, 2/22 (9 %) 4 weeks later and none at 16 to 24 week time periods ( Figure 3A) . Conversely, 13/20 (65 %) mice became hypothyroid with sub-normal T 4 levels ( Figure 3A ) and increased TSH levels ( Figure 3B ). Consistent with these data, TSAb were dominant over TBAb 4 weeks after transfer, but finally became TBAb-dominant ( Figure 4C and D) . Five mice that were hyperthyroid 4 weeks after transfer ( Figure 3A ) deserve particular attention; 2 were sacrificed at 6th week; however, the remaining 3 hyperthyroid mice eventually developed hypothyroidism.
Anti-TSHR antibodies and thyroid function following adoptive transfer of splenocytes from naive TSHR KO mice
We next examined whether anti-TSHR autoimmunity could be transferred from naïve TSHR KO mice to nude mice. Transfer of splenocytes from naïve TSHR KO mice transiently induced barely detectable antibodies in some mice ( Figure 4A ). We therefore attempted to induce anti-TSHR antibodies by treating the donor mice before transfer with anti-CD25 antibody or by treating the recipient mice after splenocyte transfer with antibodies against negative co-stimulatory molecules such as CTLA4 and PD-L1. Although a single administration of anti-CD25, anti-CTLA4 or anti-PD-L1 antibodies was ineffective ( Figure 4B to D), a combined injection of anti-CTLA4 and PD-L1 induced anti-TSHR antibodies at the 8 week time point, but this effect was transient ( Figure 4E ). Moreover, transiently induced low levels of anti-TSHR antibodies in the recipient mice treated with anti-CTLA4 and anti-PD-L1
antibodies (in Figure 4E ) had no effect on thyroid function. Thus these mice remained euthyroid for 24 weeks ( Figure 4F ).
Thyroid and retro-orbit histology
H & E staining of the thyroid glands from hyperthyroid mice 4 weeks after transfer (see Figure 3A) showed the typical feature of Graves' hyperthyroidism, namely diffuse enlargement of the glands and hypertrophy and hypercellularity of follicular epithelial cells ( Figure 5C and D, compared to control mice in A and B). Three of these mice also showed small intrathyroidal lymphocyte infiltration ( Figure 5E and F). In contrast, the thyroids of hypothyroid mice 24 weeks after transfer ( Figure 4B ) revealed a characteristic of TBAb-mediated hypothyroidism with thin epithelia without lymphocyte infiltration ( Figure 5G and H). Of interest, extensive lymphocyte infiltration was observed in 2 recipient mice that did not produce anti-TSHR antibodies (one in Figure 2A , and the other in Figure 4E ) ( Figure 5I and J).
Orbital histology was also studied in 9 recipient mice adoptively transferred with splenocytes of TSHR KO mice that were immunized with Ad-mTSHR A-subunit and subsequently depleted of Tregs. Neither macroscopic findings of orbitopathy (swelling or redness) nor signs of production of extracellular matrix or adipogenesis were detected in H & E stained sections. However, in 2 mice that were anti-TSHR antibody-positive and euthyroid through the experiments (Figures 2A and 3A) , we observed significantly increased numbers of infiltrating macrophages in both the adipose tissues and the interstitium of muscle tissues (no. 1 and 9 in Figure 6A and B). Representative photographs of control and macrophage-infiltrated orbits are provided in Figure 6C and D.
Anti-Tg antibodies following adoptive transfer of splenocytes from immunized TSHR KO mice
Development of extensive lymphocyte infiltration in the thyroids of 2 recipient mice indicates TSHR-induction of Hashimoto' thyroiditis rather than Graves' disease (15).
Therefore, anti-Tg antibodies, an immunological hallmark of Hashimoto's thyroiditis, were measured. Two mice with extensive lymphocyte infiltration, but not those with no or sparse lymphocyte infiltration, were positive for anti-Tg antibodies ( Figure 7) .
Discussion
We have recently demonstrated that immunization with Ad-mTSHR A-subunit readily induced anti-TSHR antibodies in TSHR KO mice, but not in wt mice (10) . TSHR KO mice likely have T cells reactive with higher-affinity TSHR peptides than wt mice, because of lack of thymic expression of the TSHR that is crucial for negative selection (16) . However, absence of the endogenous TSHR expression in the thyroids as well as orbital tissues of TSHR KO mice on the other hand hampered us from studying in vivo function of anti-TSHR immune response.
Therefore, we here extended these studies and performed adoptive transfer of splenocytes from TSHR KO mice to immune deficient athymic nude mice harboring the endogenous TSHR.
We found that splenocytes from Ad-mTSHR A-subunit-immunized TSHR KO mice adoptively transferred into nude mice produced readily detectable anti-TSHR antibodies for up to 24 weeks. However, sustained production of anti-TSHR antibodies was also observed for 24 weeks in immunized TSHR KO mice. Therefore, contrary to our expectation, these data do not necessarily imply that TSHR-reactive lymphocytes (primed by active immunization in the donor mice) were re-activated again by responding to the endogenous TSHR antigen in the In contrast to the successful transfer of splenocytes from immunized donors, adoptive transfer of splenocytes from naïve TSHR KO mice failed to induce strong anti-TSHR immune response. Enhancement of immune response by antibodies against negative co-stimulatory molecules alone or in combination has previously been described to be very effective at enhancing immune responses (20, 21) . However, applying this approach to adoptive transfer of splenocytes from native TSHR KO mice only transiently induced low levels of TSHR antibodies. Furthermore, our findings differ from the previous studies on a pemphigus model:
adoptive transfer of splenocytes from naïve desmoglein KO mice (an autoantigen in this disease) successfully induced pemphigus in immune-deficient mice (22, 23) . In that study, despite lower antibody titers in the recipients of splenocytes form naïve than in recipients of splenocytes from desmoglein-immunized donors, the degree of disease severity was comparable 13 in the 2 groups. The explanation for the difference between our study and theirs is unclear.
The highly successful transfer of anti-TSHR immune response from immunized TSHR KO mice to the recipient nude mice did not, however, result in the efficient induction of Graves-like hyperthyroidism. Moreover, many mice developed hypothyroidism during a long-term follow-up. Based on thyroid histology, this outcome can be attributed to conversion of TSAb-dominant antibody repertoire to TBAb-dominance, rather than to the destruction of the thyroid glands by lymphocyte infiltration. Similar conversion of TSAb to TBAb was observed in TSHR KO mice immunized with Ad-mTSHR A-subunit and also has been demonstrated in some Grave' patients previously (24, 25) . It may be highly relevant to dissect the mechanisms underlying this phenomenon for developing new therapeutic strategies against Graves' disease.
Although the incidence was very low, some mice developed variable levels of intrathyroidal Graves' orbitopathy is one of hallmarks of extrathyroidal manifestations accompanying Graves' disease. Interestingly, many researchers have come to recognize that the TSHR is the primary autoantigen in this condition, although it is unclear whether anti-TSHR antibodies themselves are pathogenic or TSHR-reactive T lymphocytes are the primary mediators (3). It has also been reported that the receptor for insulin-like growth factor may be a second antigen (26) . Furthermore, other candidate autoantigens have also been reported including calsequestrin, collagen XIII and G2s (27) , which may however be secondary responses to tissue destruction (3). In conclusion, we established a system for studying the responses to the mouse TSHR in mice. We believe that, rather than immunization with the receptor of human origin, use of mouse TSHR, as an autoantigen itself, will provide an optimal mouse model(s) harboring both
Graves' hyperthyroidism and orbitopathy. 
